Tanja Obradovic: NADINA trial making history at ASCO2024 plenary session

Tanja Obradovic shared on LinkedIn:   .

“NADINA trial making history today at ASCO2024 plenary session. Clear superiority of neoadjuvant Ipilimumab + Nivolumab compared to adjuvant Nivolumab in stage III resectable melanoma. EFS as presented today below. Also, just out full article in NEJM.

Very important finding for melanoma patients where new standard of care of two cycles of neoadjuvant immunotherapy treatment will deliver outstanding benefit while allowing avoidance of toxicities under old approach of long term adjuvant therapy. Results are certainly prompting questions about applicability to adjuvant approach in other tumor indications as well as further fostering debate about neoadjuvant vs adjuvant contribution when two regimens are combined.”

Source: Tanja Obradovic/LinkedIn

Tanja Obradovic is the Vice President of Oncology Scientific Affairs at ICON PLCh. She has over 20 years of clinical research experience and has led major pharmaceutical companies for 13 years. Her research focuses on small molecules, antibodies, cell and gene therapy, and major immunotherapy of PD1 inhibitors.